Genetic association of zinc transporter 8 (ZnT8) autoantibodies in type 1 diabetes cases by Howson, J. M. M. et al.
ARTICLE
Genetic association of zinc transporter 8 (ZnT8)
autoantibodies in type 1 diabetes cases
J. M. M. Howson & S. Krause & H. Stevens & D. J. Smyth &
J. M. Wenzlau & E. Bonifacio & J. Hutton & A. G. Ziegler &
J. A. Todd & P. Achenbach
Received: 23 December 2011 /Accepted: 23 February 2012 /Published online: 12 April 2012
#
Abstract
Aims/hypothesis Autoantibodiestozinctransporter8(ZnT8A)
are associated with risk of type 1 diabetes. Apart from the
SLC30A8 gene itself, little is known about the genetic basis of
ZnT8A.WehypothesisethatotherlociinadditiontoSLC30A8
are associated with ZnT8A.
Methods ThelevelsofZnT8Aweremeasuredin2,239British
type 1 diabetic individuals diagnosed before age 17 years,
with a median duration of diabetes of 4 years. Cases were
tested at over 775,000 loci genome wide (including 53 type 1
diabetes associated regions) for association with positivity for
ZnT8A.ZnT8Awerealsomeasuredinanindependent dataset
of 855 family members with type 1 diabetes.
Results Only FCRL3 on chromosome 1q23.1 and the
HLA class I region were associated with positivity for
ZnT8A. rs7522061T>C was the most associated single
nucleotide polymorphism (SNP) in the FCRL3 region
(p01.13×10
−16). The association was confirmed in the
family dataset (p≤9.20×10
−4). rs9258750A>G was the
most associated variant in the HLA region (p02.06×10
−9 and
p00.0014 in family cases). The presence of ZnT8A was not
associated with HLA-DRB1, HLA-DQB1, HLA-A, HLA-B or
HLA-C (p>0.05). Unexpectedly, the two loci associated with
the presence of ZnT8A did not alter risk of having type 1
diabetes, and the 53 type 1 diabetes risk loci did not influence
positivity for ZnT8A, despite them being disease specific.
Conclusions/interpretation ZnT8A are not primary patho-
genic factors in type 1 diabetes. Nevertheless, ZnT8A test-
ing in combination with other autoantibodies facilitates
disease prediction, despite the biomarker not being under
the same genetic control as the disease.
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Autoantibodies to glutamic acid decarboxylase (GADA),
insulinoma-associated antigen-2 (IA-2A) and insulin (IAA)
and islet cell autoantibodies (ICA) have long been estab-
lished as associated with the development of type 1 diabetes,
with over 90% of newly diagnosed cases positive for at least
one of these autoantibodies [1–4]. Most recently, autoanti-
bodies to the pancreatic beta cell-specific protein, zinc trans-
porter 8 (ZnT8A), have also been shown to be associated
with type 1 diabetes [5]. Over 60% of newly diagnosed cases
are positive for ZnT8A, and 4% of cases are positive for
ZnT8A only [5–7], thus suggesting their utility as a predic-
tive and diagnostic marker in type 1 diabetes [8–10]. The
percentage of newly diagnosed cases positive for ZnT8A (as
well as the magnitude of the ZnT8A titre) has been positively
correlated with an older age at diagnosis of type 1 diabetes in
children [5, 11] and has been shown to decline following
diagnosis of type 1 diabetes [12, 13]. The same correlations
have also been found with IA-2A and GADA [14].
The ZnT8 protein is encoded by the SLC30A8 gene,
which is convincingly associated with type 2 diabetes risk
atthesinglenucleotidepolymorphism(SNP)rs13266634C>T,
an amino acid substitution R325W [15–17]. Although this
amino acid variant determines the epitope specificity of
ZnT8A in type 1 diabetes, either ZnT8RA or ZnT8WA
[8, 11], its association with risk of the disease itself is less
clear [18–20].
ZnT8RA have been reported as associated with HLA-
DQB1*0302 genotypes [7] and both ZnT8RA and ZnT8WA
have been correlated with HLA-DQB1*0604 haplotypes [8].
Noothergenetic associationshavebeen reportedwithZnT8A
to date. Given the association of ZnT8Awith type 1 diabetes,
the 52non-HLA regions ofthe genomeassociatedwithtype1
diabetes (www.t1dbase.org, accessed 13 December 2011),
have a high prior probability of also being associated with
ZnT8A positivity. Therefore, we measured ZnT8A (R and W
epitopes) in 2,239 British individuals withtype 1 diabetes and
tested the known type 1 diabetes regions for association with
presence of ZnT8A. A genome-wide association study
(GWAS) was also performed to further test for genetic deter-
minants ofZnT8A.Finally, were-examined the association of
rs13266634 in SLC30A8 with ZnT8A and type 1 diabetes.
Methods
Samples A total of 2,239 British type 1 diabetic individuals
diagnosed before the age of 17 years were included in the
study (Table 1). These constitute a randomly selected subset
of the full collection of 8,000 cases that have been described
elsewhere [14]. An independent dataset of 855 family
members within 2 years of diagnosis of type 1 diabetes
(average age at diagnosis of 12.0 years) was taken from
the type 1 diabetes genetics consortium (T1DGC) affected
sib-pair families and have been described previously [21].
All samples were of white European ancestry.
Autoantibody measurement ZnT8Awere measured in serum
by protein A radiobinding assays as previously described
[20] using COOH-terminal (aa268-369) constructs of the
ZnT8 R325 (ZnT8RA) and W325 (ZnT8WA) variants,
respectively. cDNAs for the preparation of radioligands by
in vitro transcription–translation were kind gifts of V.
Lampasona (San Raffaele Scientific Institute, Milan, Italy).
Samples were considered ZnT8A positive if antibodies to at
least one of the ZnT8 variants (ZnT8RA and/or ZnT8WA)
were found. Performance in the Diabetes Antibody Stan-
dardization Program 2009 workshop is shown as ‘laboratory
121’ in a published report [22]. Details of the GADA and
IA-2A assays, and the ZnT8A assay in T1DGC families,
have been reported previously [14, 21, 22].
Genotyping The HLA-DRB1, HLA-DQB1, HLA-A, HLA-B
and HLA-C genes were typed at four digit resolution using
Dynal RELI SSO assays (Invitrogen, Paisley, UK) as de-
tailed elsewhere [23]. A subset of cases was genotyped at
HLA-DRB1 and HLA-DQB1 using Roche Molecular Sys-
tems SSO reverse dot blot technology (Roche Molecular
Systems, Pleasanton, CA, USA). The T1DGC GWAS geno-
typed 487,592 SNPs that passed quality control checks
(2,420 within the extended MHC) using the Illumina 550K
Infinium platform [24] (Illumina, San Diego, CA, USA);
and 362,838 SNPs (1,687 within the extended MHC) study
were genotyped using the Affymetrix GeneChip Human
Mapping 500K Array set (Affymetrix, Santa Clara, CA,
USA) for the Wellcome Trust Case Control Consortium
(WTCCC) GWAS [25]; 75,181 were common to both plat-
forms. Follow-upSNPs were genotyped blindto ZnT8A status
using the TaqMan 5′ nuclease assay (Applied Biosystems,
Warrington, UK) according to the manufacturer's protocols.
All genotyping in the family samples used TaqMan. Two
operators scored genotypes blind to disease status.
Statistics All statistical analyses were performed in R
(www.r-project.org, accessed 13 December 2011) [26]o r
STATA (www.stata.com, accessed 13 December 2011). As-
sociation with ZnT8A (including R and W epitopes) was
assessed using logistic regression models, with autoanti-
body positivity as the outcome variable and genotype as
the predictor. Covariates, age at diagnosis and duration of
diabetes were included in the regression models to account
for the decrease in positivity for ZnT8A with duration of
diabetes and the increase in the number of cases positive for
ZnT8A with increasing age at diagnosis. For family analy-
ses, robust variance estimates were used to account for non-
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imputed in the GWAS datasets using a common set of 1,500
controls genotyped on both platforms as reported previously
[24]. Imputed genotypes were weighted by their posterior
expectation in the regression models. To assess which autoanti-
body was associated with rs7522061, ZnT8A and IA-2Awere
usedas predictorsof rs7522061genotype inregressionmodels.
Results
ZnT8A was measured in 2,239 British type 1 diabetic indi-
viduals. Cases positive for ZnT8A were associated with an
older age at diagnosis (p03.12×10
−16) and a shorter dura-
tion of diabetes (p01.10×10
−57), as were both the ZnT8RA
and ZnT8WA epitopes (p<5×10
−14; Table 1). Whilst the
highest positivity for ZnT8Awas observed in cases with the
shortest duration of disease (≤2 years), 10% of cases who
had had diabetes for ≥9 years were still positive for ZnT8A
(Table 2). Therefore, both age at diagnosis and duration of
diabetes were included as covariates in all tests of associa-
tion with positivity for ZnT8A. This accounts for the
decrease in positivity for ZnT8A with duration of disease
and earlier age at diagnosis in the statistical association tests,
such that all positive associations obtained can be attributed
to the genetic variant tested.
A subset of 1,307 cases with ZnT8A measurements had
previously been tested for GADA and IA-2A [14, 21]. Of
these, just 277 (21%) were negative for all three autoanti-
bodies and 28 were only positive for ZnT8A. There was a
strong association of positivity for ZnT8A with both IA-2A
and GADA positivity, after accounting for age at diagnosis
and duration of disease (OR 4.45 [95% CI 3.32, 5.99] p0
8.46×10
−26 and OR 1.63 [95% CI 1.24, 2.14] p05.04×
10
−4, respectively); 81% of ZnT8A positives were also
positive for IA-2A, whereas 63% were positive for GADA.
Table 1 Phenotypes of the type
1 diabetic cases by positivity for
ZnT8A status
Variable Cases overall ZnT8A ZnT8WA ZnT8RA
Positive Negative Positive Positive
n, all samples 2,239 752 1,487 531 642
Age at diagnosis
Mean (SD)/year 7.57 (3.91) 8.99 (3.36) 6.86 (3.98) 9.14 (3.37) 9.08 (3.31)
Median/year 7 9 7 10 9.5
Duration of diabetes
Mean (SD)/year 6.61 (7.53) 3.45 (3.83) 8.27 (8.54) 3.38 (3.84) 3.34 (3.60)
Median/year 4 2 6 2 2
Age
Mean (SD)/year 14.18 (8.05) 12.43 (4.75) 15.13 (9.29) 12.52 (4.70) 12.41 (4.53)
Median/year 13 12 13 13 12
Sex
Male 1,119 (0.50) 368 (0.49) 751 (0.51) 270 (0.51) 319 (0.50)
Female 1,119 (0.50) 383 (0.51) 736 (0.49) 261 (0.49) 322 (0.50)
Table 2 Positivity for ZnT8A in
type 1 diabetes cases by quartiles
of the duration of diabetes
distribution
n number of samples
Duration ZnT8A positive ZnT8WA positive ZnT8RA positive ZnT8A negative
n (%) n (%) n (%) n (%)
British cases
≤2 years 389 (58) 283 (42) 340 (51) 279 (42)
3–4 years 187 (38) 128 (26) 158 (32) 301 (62)
5–8 years 122 (22) 81 (15) 104 (19) 426 (78)
≥9 years 54 (10) 39 (7) 40 (8) 479 (90)
T1DGC families
<2 years 523 (60) 412 (54) 462 (61) 345 (40)
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Outside of the HLA, no evidence of association with posi-
tivity for ZnT8A was obtained in the type 1 diabetes asso-
ciated regions with the British cases (p>0.03). None of the
classical HLA loci, HLA-DRB1, HLA-DQB1, HLA-A, HLA-B
and HLA-C, were associated with ZnT8A (p>0.05; Fig. 1).
Evidence of association in the HLA region mapped to the
class I region (Fig. 1). The most strongly associated SNP was
rs2855812 (p02.25×10
−5)i nMICB in the T1DGC cases, and
rs9258750 (p03.00×10
−4)n e a rHLA-A in the WTCCC cases.
The genotyping of these SNPs was extended to over 2,100
cases in which ZnT8Awas measured (electronic supplemen-
tary material [ESM] Table 1). The rs9258750 SNP showed
more evidence of association with positivity for ZnT8A (p0
2.06×10
−9; OR for the major A allele 1.82 [95% CI 1.49,
2.23]) than rs2855812 (p05.80×10
−5; OR for the minor T
allele 1.33 [95% CI 1.16, 1.53]). The two SNPs were not in
linkage disequilibrium (LD) (r
200.02, D′00.33) and hence
appear to mark independent effects (p07.2×10
−4 for the ad-
dition of rs2855812 to rs9258750, and p05.83×10
−8 for the
addition of rs9258750 to rs2855812). rs9258750 was in LD
with HLA-A*24 (r
200.54, D′00.98). HLA-A*24 was associ-
ated with ZnT8A positivity (p02.03×10
−4), but this was due
to rs9258750: p00.95 for the addition of HLA-A*24 to
rs9258750, compared with p00.0015 for the addition of
rs9258750 to HLA-A*24 in regression models. The associa-
tionofrs9258750 withpositivityfor ZnT8Awas confirmed in
an independent family dataset of white European ancestry
(p00.0014; OR for the major A allele 1.57 [95% CI 1.19,
2.06] in the 833 affected family members successfully
genotyped).
Genome-wide association
Having found no evidence of association with positivity for
ZnT8A in the type 1 diabetes associated regions, the search
was extended genome wide. Up to a maximum of 2,142
cases were analysed at 775,249 SNPs across the genome.
Only the FCRL3 gene region on chromosome 1 attained
significance at a GWAS level (p<5×10
−8) with all SNPs
outside of this region having p values above 1×10
−6 (Fig. 2
and ESM Fig. 1). The most associated SNP, rs7522061, (p0
1.13×10
−16) is located in exon 4 of the FCRL3 gene
(Ensembl version 63) and is in LD with rs7528684 (r
200.89
in British controls), which has previously been shown to be
associated with IA-2A in type 1 diabetes cases [21, 28]. The
region is also associated with Graves' disease and thyroid
peroxidase autoantibody positivity at rs11264798 [21, 25].
Neither rs7528684 (the IA-2A associated variant) nor
rs11264798 (the Graves' disease associated variant) were
genotyped as part of the GWAS, but had been genotyped
previously using TaqMan [21]. Both SNPs were associated
with positivity for ZnT8A (rs7528684, p01.79×10
−16;O R
for the major A allele 1.81 [95% CI 1.56, 2.09] and
rs11264798 p04.86×10
−14; OR for the C allele 1.72 [95%
CI 1.48, 1.98]). Only the WTCCC samples were genotyped
at rs7522061 (with imputation used for the remaining sam-
ples in the GWAS), and so this was extended to 2,131 cases
by TaqMan genotyping (Table 3). Whilst rs7522061
accounted for the association at rs11264798, both
rs7522061 and rs7528684 appear to be marking the same
association, as their effects could not be distinguished in the
2,088 cases genotyped at both loci: rs7528684 did not
improve a model with rs7522061 (p00.15) and conversely,
rs7522061 did not improve a model with rs7528684 (p0
0.10). Given that IA-2A and ZnT8A are correlated, we tested
whether the association with positivity for ZnT8A at FCRL3
Fig. 1 Association of ZnT8A with SNPs in the MHC region of
chromosome 6. SNPs are analysed in up to 1,021 type 1 diabetes cases
at the WTCCC SNPs (crosses) and up to 1,123 type 1 diabetes cases at
the T1DGC SNPs (dots). −log(p value for association with ZnT8A
positivity) is plotted against physical position in megabases (Mb). The
physical locations of the HLA classical loci are also given
Fig. 2 Association of positivity for ZnT8Awith SNPs on chromosome
1 in up to 2,142 type 1 diabetes cases
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cases in a model that included both ZnT8A and IA-2A,
positivity for ZnT8A predicted the rs7522061 genotype
(p05.51×10
−11) and IA-2A positivity did not (p00.10).
The association at FCRL3 was confirmed in up to 855
affected family members of white European ancestry. Con-
firmation of association with ZnT8A was obtained at
rs7522061, rs7528684 and rs11264798 (p01.20×10
−4,
3.14×10
−4 and 9.20×10
−4, respectively) with the same di-
rection of effect as in the British cases (OR for the Tallele at
rs7522061, 1.50 [95% CI 1.22, 1.84]; Table 3).
Association of ZnT8A with SLC30A8
In the GWAS, whilst evidence of association with positivity
for ZnT8Awas obtained at rs13266634/R325Win SLC30A8
(p05.29×10
−5), it was not at a level required for GWAS
significance. As genotypes were only available for those
samples genotyped using the Illumina platform, rs13266634
wasgenotypedinallsamplesusingTaqMan(asdetailedinthe
Methods). The SNP was associated withpositivity for ZnT8A
(p03.66×10
−11). However, a multiplicative allelic effects
model did not fit the data. The minor T/T homozygous geno-
type was associated with ZnT8A positivity and the heterozy-
gous C/T genotype with absence of ZnT8A (Table 4).
Analysis of the two epitopes, ZnT8WA and ZnT8RA,
revealed that the T allele at rs13266634 was associated with
ZnT8WA positivity (p09.26×10
−27) and ZnT8RA negativity
(p07.20×10
−17; Table 4). This inverse association of the two
ZnT8A epitopes with rs13266634 accounted fully for the
deviation from a multiplicative allelic effects model with
positivity for ZnT8A overall. Importantly, this SNP is not
associated with type 1 diabetes overall (p00.15 in 7,680
British type 1 diabetes cases and 7,200 British controls;
ESM Table 2).
Discussion
We have obtained convincing evidence of association be-
tween positivity for ZnT8A and the nonsynonymous SNP,
rs7522061, in FCRL3, and in our datasets this association
was indistinguishable from the association with the non-
coding SNP, rs7528684. The T allele of rs7522061, which
is associated with positivity for ZnT8A, alters the amino
acid sequence (Asp to Asn), which could alter protein func-
tion and/or RNA stability/splicing. Only in relation to mul-
tiple sclerosis have there been reports of this SNP being
associated; the same study also reported disease association
with rs7528684 [29]. The minor G allele at rs7528684 is
associated with risk of rheumatoid arthritis and systemic
lupus erythematosus [30], protection from autoimmune
Addison disease [31] and multiple sclerosis [29], and has
Table 3 Association of positivity for ZnT8A with rs7522061 T>C in
FCRL3
rs7522061 T allele p value
n (frequency) OR [95% CI]
Positive Negative
British cases
ZnT8A 876 (0.61) 1,395 (0.49) 1.82 [1.57, 2.10] 1.13×10
−16
ZnT8WA 630 (0.62) 1,641 (0.51) 1.70 [1.45, 1.98] 8.13×10
−12
ZnT8RA 735 (0.61) 1,536 (0.50) 1.65 [1.42, 1.91] 1.74×10
−11
Family samples
ZnT8A 601 (0.59) 322 (0.49) 1.50 [1.22, 1.84] 1.20×10
−4
The minor allele is negatively associated with the presence of ZnT8A
in both the British cases and the family samples, so ORs and allele
frequencies are given for the major T allele. The association of
rs7522061 with ZnT8A is consistent across both ZnT8WA and
ZnT8RA epitopes
Table 4 Association of rs13266634 in SLC30A8 with positivity for ZnT8A in 2,191 type 1 diabetes cases
rs13266634 ZnT8A ZnT8WA ZnT8RA
n (frequency) OR [95% CI] n (frequency) OR [95% CI] n (frequency) OR [95% CI]
Positive Negative Positive Negative Positive Negative
T 500 (0.34) 928 (0.32) 1.07 [0.93, 1.24] 478 (0.46) 950 (0.28) 2.38 [2.02, 2.80] 310 (0.25) 1,118 (0.36) 0.51 [0.43, 0.60]
C/C 348 (0.47) 651 (0.45) 1.00 (reference) 152 (0.29) 847 (0.51) 1.00 (reference) 348 (0.56) 651 (0.42) 1.00 (reference)
C/T 272 (0.37) 684 (0.47) 0.64 [0.52, 0.78] 254 (0.49) 702 (0.42) 2.01 [1.59, 2.55] 246 (0.39) 710 (0.45) 0.54 [0.44, 0.67]
T/T 114 (0.16) 122 (0.08) 1.90 [1.38, 2.62] 112 (0.22) 124 (0.07) 6.31 [4.48, 8.88] 32 (0.05) 204 (0.13) 0.23 [0.15, 0.35]
p value 3.66×10
−11 a 9.26×10
−27 b 7.20×10
−17 b
n number of alleles or genotypes
aNote that the multiplicative model did not fit the data, p06.44×10
−12, hence the p value reported is for a model that does not assume a specific
mode of inheritance
bNote the multiplicative model was an appropriate approximation for the association with ZnT8WA (p00.056) and ZnT8RA (p00.38)
1982 Diabetologia (2012) 55:1978–1984been found to alter the binding affinity of nuclear factor-κΒ
[30], making it a good functional candidate SNP. Interest-
ingly, FCRL3 is not associated with type 1 diabetes risk
[21], even though it is strongly associated with IA-2A
positivity [21, 28]. We have shown here that this association
is probably due to a primary association with positivity for
ZnT8A and not with IA-2A positivity directly. The associa-
tion with positivity for ZnT8A was marked equally well by
rs7522061 or rs7528684, and consequently, further work is
required to unravel the precise nature of the association with
the presence of ZnT8A in the FCRL3 region and the mecha-
nisms involved.
None of the regions known to be associated with type 1
diabetes, outside of the HLA, were associated with positi-
vity for ZnT8A. Interestingly, evidence of association with
positivity for ZnT8A was confined to the HLA class I
region, but the most associated variant, rs9258750, was
not associated with type 1 diabetes (p00.13 in 8,232 British
cases and 9,757 British controls; data not shown). The
known associations of IA-2A with HLA-A*24 [14, 32] and
of GADA with rs9266722 in HLA class I [14] were inde-
pendent of the ZnT8A associations described in the present
study. In contrast to previous reports in smaller sample sets,
no association with HLA-DQB1*0302, *0604, *04 alleles
and ZnT8A was obtained (p>0.15), neither with positivity
for ZnT8RA (p>0.15) nor ZnT8WA (p>0.16).
Our study is the largest of its kind to date, using 2,239
case samples, 70% of whom had had ZnT8A measured,
having been diagnosed with type 1 diabetes more than
2 years earlier. Therefore, we have been able to confirm
recent reports that showed that positivity for ZnT8A
declines after diagnosis of disease [12, 13]. Approximately
40% of cases tested for ZnT8A who have had diabetes for
4 years are expected to test positive compared with 62% at
diagnosis [12]. In our samples it was comparable (Table 2).
A consequence of this decline in positivity for ZnT8A with
duration of diabetes is that the rate of ZnT8A negative
samples will be elevated amongst cases with longer disease
duration. Consequently, almost half the cases classed as
ZnT8A negative who had had diabetes for 9 or more years
would probably have tested positive had they been tested at
diagnosis. This causes the association signal at some loci to
be diluted in these samples, but does not affect the validity
of the positive associations detected. The HLA and FCRL3
associations with ZnT8A in cases who have had diabetes for
≤2 years are of comparable strength to those who have had
diabetes for ≥9 years (ESM Tables 3 and 4). All positive
associations were confirmed in the cases from the families
affected by type 1 diabetes, all of whom were tested within
2 years of diagnosis. The lack of association outside of the
HLA and FCRL3 may be attributable to lack of power,
which was exacerbated by the increased frequency of
ZnT8A negativity amongst samples with a longer duration
of disease. The inverse correlation of positivity for ZnT8A
with duration of diabetes was not known when we designed
our study, and hence, the statistical power of future studies
into the genetic architecture of presence of ZnT8A would
benefit from using cases as close to diagnosis as possible, as
we have done for the replication in family samples.
For autoantibodies to be causal for type 1 diabetes, the
variants associated with risk of type 1 diabetes would also
be expected tobe associated withautoantibody positivity. Our
results, therefore, indicate that autoantibodies to ZnT8 are a
downstream event to the primary genetic pathogenesisof type
1 diabetes. Given their specificity for type 1 diabetes [6],
however, this does not detract from their well established
value, in combination with other autoantibodies, in assessing
risk of the disease [6, 10, 20], but does illustrate how useful
biomarkers need not necessarily have associations withgenet-
ic markers that confer susceptibility to disease.
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